# Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

> **NCT00182702** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** ixabepilone
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00182702
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2013-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00182702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00182702, "Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00182702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*